Share on StockTwits

Meridian Bioscience (NASDAQ:VIVO) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a report released on Wednesday. They currently have a $18.40 price objective on the stock. Zacks‘s price objective points to a potential downside of 5.01% from the company’s current price.

Shares of Meridian Bioscience (NASDAQ:VIVO) traded down 0.62% on Wednesday, hitting $19.25. 90,658 shares of the company’s stock traded hands. Meridian Bioscience has a 52-week low of $19.14 and a 52-week high of $27.72. The stock has a 50-day moving average of $20.09 and a 200-day moving average of $20.6. The company has a market cap of $800.2 million and a P/E ratio of 22.79.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, July 24th. The company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by $0.01. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $47.96 million. During the same quarter in the previous year, the company posted $0.24 earnings per share. The company’s revenue for the quarter was up .2% on a year-over-year basis. On average, analysts predict that Meridian Bioscience will post $0.86 earnings per share for the current fiscal year.

Meridian Bioscience, Inc (NASDAQ:VIVO) is a fully-integrated life science company.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.